The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
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Supplementary Figure 1: Ordered bar plot of key gene expression associations across TC-6 subgroups. Gene expression features of TC-6 subgroups are distinct. Each subgroup has a primary dysregulated D-group cyclin and/or translocation genes and secondary genes that help define its members, e.g. CCND1-11q13 cases overexpress CCND1 (primary) and SLC8A1 (secondary) while MMSET cases overexpress WHSC1 (or MMSET), CCND2 and DSG2 (secondary). The D1-HRD subgroup has intermediate expression of CCND1 with elevated expression of hyperdiploid-related genes located on odd-numbered chromosomes (ISL2, TNFSF10). The D2 subgroup has high CCND2 and PTP4A3 expression without an IGH translocation. The CCND1-11q13 subgroup is composed of cases with t(11;14) IGH translocations, elevated expression of CCND1 and SLC8A1, and over expression of the CD20 (MS4A1) in 54% of cases. CCND3-6p21 is a rare subtype with spiked expression of CCND3 often accompanied by high USP49 expression. The MMSET subgroup includes all cases with 4p16 IGH translocations, elevated expression of MMSET (WHSC1), with or without high expression of FGFR3. The MAF subgroup is composed of cases of all three subtypes of MAF-associated IGH translocations: 16q23 (c-MAF), 20q12 (MAFB), and 8q24 (MAFA, rare). These subtypes have elevated expression of MAF-associated genes such as NUAK1, ITGB7, and ARID5A with spiked expression in MAF, MAFB, or MAFA, respectively. We note that RNA-Seq analysis offers confirmation of 8q24-MAFA cases as probes for MAFA transcripts are available. Log2 expression values for key genes are shown, sorted by cyclin D expression. Expression values shown range from a minimum raw value of 50 and to a maximum of 7,500. associations between gene expression and presence of RAS-RAF mutations exist across the TC-6 subgroups. In particular, the D1-HRD, D2, and CCND1-11q13 subgroups have a significant association where high expression of DKK1, DUSP6, SPRED2, and ETV5 is observed in the presence of RAS-RAF activating mutations. Additional genes with significant association with RAS-RAF mutations were included in each subgroup heatmap, e.g. the expression of BIRC3 and RRAS2 are significantly negatively associated with presence of RAS-RAF activating mutations in the D1-HRD subgroup. The top section of each panel shows a block plot of key alterations across the TC-6 subgroups shaded according to legend. Heatmap of up and down-regulated genes, colored in red and blue, includes additional genes for each subgroup selected systematically according to regularized regression (lasso). Cases are sorted from left to right according to likelihood of RAS-RAF mutation as predicted from GEP-based subgroup signatures.
Supplementary Figure 4:
Kaplan-Meier overall survival curves for RAS-RAF and FGFR3 mutations by TC-6 subgroups. We observe that in the subgroups that are enriched for NRAS mutations at Q61, mutations of NRAS at Q61 impart a less favorable outcome in CCND1-11q13 subgroup than in D1-HRD and D2 subgroups. Furthermore, RAS-RAF mutations in MMSET myeloma have less favorable outcome than cases with FGFR3 mutations or without RAS-RAF mutations.
